Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 27;13(9):213. doi: 10.3390/ph13090213

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Pre-treatment with H₂S protects RGC against ischemia-reperfusion injury in vivo. (A–C) Representative fluorescence microscopy of Brn3a staining of retinal explants 24 h after inducing ischemia/reperfusion injury in vivo. (D) Compared to the contralateral control (1310.6 ± 236.4 RGC/mm²), ischemia-reperfusion injury resulted in significant RGC loss in experimental eyes (1101.7 ± 116.4 RGC/mm²). Pretreatment with GYY4137 showed a significant reduction of RGC loss in vivo (1295.4 ± 136.1 RGC/mm²). Total number of RGC between control and H₂S treated group is not significantly different (*** p < 0.0005, n = 6/group, means ± SD, scale bar = 50 μm).